Advertisement


Bijal D. Shah, MD, on What ALL Tells Us About CAR T Cells

NCCN 2018 Annual Conference

Advertisement

Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses key studies of CAR T-cell therapy in relapsed B-cell ALL and the adverse events that this treatment may cause.



Related Videos

Breast Cancer

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications ...

Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: Management Approaches

James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate...

Issues in Oncology

Lee N. Newcomer, MD, on Managed Care in America: Expert Perspective

Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care...

Colorectal Cancer
Immunotherapy

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy c...

Breast Cancer

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Treatment Update

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targ...

Advertisement

Advertisement



;
Advertisement